Verkada introduces new dual-head camera, enhanced alerting capabilities
SAN MATEO, Calif., May 8, 2025 /PRNewswire/ — Verkada, a leader in cloud-based physical security, today announced its new dual head camera and enhanced alerting capabilities on its Command platform, along with a wide range of updates that will make it even easier for its customers around the world to keep their people and places safe.
Verkada is expanding its multisensor line with a new dual head camera, the CY53-E Two-Camera Multisensor. With two viewing angles from a single install point, an advanced onboard processor, and 2.55x optical zoom in each sensor, organizations can minimize potential blindspots with increased visibility and AI-based analytics and alerts.
Verkada also introduced enhanced alerting capabilities that enable customers to integrate Verkada Guest, LPR, Alarm events, and Helix events into Verkada's Alert Inbox. This means that security teams at a manufacturing site can now receive an alert anytime a visitor or contractor arrives on-site, or a luxury retailer can get an alert anytime a customer purchases a specific high-value product. This will significantly enhance its customers' ability to monitor, assess, and respond to critical issues.
'Each new product and feature that we introduce is purpose-built to serve our customers' evolving needs,' said Brandon Davito, Senior Vice President of Product and Operations at Verkada. 'Whether it's our new two-camera multisensor to monitor entry and exit points more effectively or our customizable, cross-product alerting capabilities, every addition to Verkada's platform is designed to support efficient enterprise deployments today and scale with our customers into the future.'
Verkada also announced a range of additional product and platform updates, including:
Deeper integration between Alarms and Access Control with the addition of door event triggers – door opened, door held open, and door forced open events – to the Verkada Alarms solution. Like intrusion sensors, any access control alarm trigger can be assigned to alarm partitions, paired with cameras for video verification, and subject to the same arm/disarm methods as schedules or key codes. Learn more.
Features designed for enhanced emergency response with Verkada's Intercom, including the ability to create a unique, local phone number associated with outgoing Intercom calls. This not only gives organizations more visibility and the ability to call and 'talk down' to a specific intercom, but also enables them to configure 911 dialing for blue light deployments or emergency scenarios. Learn more.
Continued improvement to the visitor experience with an expanded set of on-demand credentials that organizations can grant for temporary building access, which now includes PIN and QR code options, as well as a new Cisco Meraki integration that provides guests with automatic access to the WiFi network at check-in. Learn more.
Enhanced features and functionalities that speed up investigations, including the ability to group persons of interest into lists and the expansion of History Player Search to include vehicles. Learn more.
New deterrence capabilities, with a wireless siren and strobe that can be triggered by Verkada Alarms. Verkada is also enhancing large site support across its Alarms product with the ability to now connect an unlimited number of its BK22 keypads with one ethernet drop and reducing wiring costs with the ability to daisy-chain up to four of its BE32 expanders. Learn more.
Enhanced functionality for customers on-the-go with Verkada Guest, LPR functionality, Floorplans, and 'My Account' page now available in the Command mobile app. Learn more.
Refreshed UI and search experience in Command that will make it even easier for security administrators to navigate their settings on Verkada's platform, with instant filtering and new feature groupings. Verkada customers can now simply type keywords related to any Command admin setting and find what they need. Learn more.
About Verkada Designed with simplicity in mind, Verkada's six product lines — video security cameras, access control, environmental sensors, alarms, workplace, and intercoms — provide unparalleled building security through an integrated, cloud-based software platform. Over 30,000 organizations across 93 countries worldwide, including 91 of the Fortune 500, trust Verkada as their physical security layer for easier management, intelligent control, and scalable deployments. For more information, please visit www.verkada.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Economic Uncertainty Continues as Inventory Levels Rise Across Truck and Construction Equipment Markets
LINCOLN, Neb., June 4, 2025 /PRNewswire/ — New Sandhills Global market reports show inventory levels rising month over month for U.S. used truck, semi-trailer, and construction equipment markets on Sandhills platforms, which include and Inventory levels in the used heavy-duty truck and semi-trailer markets are trending sideways despite monthly increases. However, used medium-duty truck inventory levels are continuing a steady upward trend, while asking and auction values remain on a downward trend. 'Uncertainty has filled the truck market,' says Truck Paper Manager Scott Lubischer. 'Dealers are selling trucks not because they are upgrades, but because people still need to operate. Dealers are lowering prices to drive sales, but they are feeling the effects of slowed port activity, lower freight volumes, and tariffs.' In the used heavy- and medium-duty construction equipment markets, Sandhills has observed inventory levels trending downward despite small monthly upticks in May. Asking prices and auction values dipped lower across all used construction equipment markets; trend lines are holding steady, but if value drops persist, they may also shift trend lines downward. 'Used equipment dealers are navigating a mixed market,' says Director of North America Construction Stephanie Olberding. 'Seasonal drops in demand have contributed to the slight heavy-duty construction inventory increases noted in the May reports.' The key metric in all of Sandhills' market reports is the Sandhills Equipment Value Index (EVI). Buyers and sellers can use the information in the Sandhills EVI to monitor equipment markets and maximize returns on acquisition, liquidation, and related business decisions. The Sandhills EVI data include equipment available in auction and retail markets and model-year equipment actively in use. EVI spread measures the percentage difference between asking and auction values. Additional Market Report TakeawaysSandhills market reports highlight the most significant changes in Sandhills' used heavy-duty truck, semi-trailer, farm machinery, and construction equipment markets. Key points from the current reports are listed below. Full reports are available upon request. U.S. Heavy-Duty Trucks Inventory levels in this market rose 3.9% month over month in May and fell 21.83% year over year, but maintained a steady trend. Used sleeper trucks led other categories in inventory level changes, both M/M, with a 6.38% increase, and YOY, with a 35.37% decrease. Asking values in this market have also been trending sideways, with a marginal 0.19% increase M/M and a 2.51% decrease YOY in May. The used sleeper truck category had the largest M/M asking value increase at 1.29%, while used day cab trucks had the largest YOY decrease at 5.62%. Auction values posted small increases of 0.67% M/M and 0.38% YOY in May and are trending upward. Used sleeper trucks led other categories in M/M auction value increases, up 2.63%, while used day cab trucks posted the largest YOY auction value drop at 7.10%. U.S. Used Semi-Trailers Inventory levels in the U.S. used semi-trailer market have maintained a steady trend. In May, inventory increased by 3.41% M/M, but was 11.2% lower than year-ago levels. The used reefer trailer category showed the largest M/M inventory increase at 10.49%, while used dry van trailers had the largest per-category YOY decrease at 18.29%. Asking values are trending up, with a 0.91% M/M increase and a 2.92% YOY decrease in May. The used reefer trailer category drove M/M asking value increases with a 6.31% jump. The used flatbed trailer category led in YOY asking value decreases, down 4.05%. Although auction values decreased by 0.81% M/M in May, they increased 2.05% YOY and are trending up. Notably, used dry van trailers showed the largest M/M auction value decrease at 5.31%, and used flatbed trailers had the largest YOY increase at 3.67%. U.S. Used Medium-Duty Trucks Inventory levels in the U.S. used medium-duty trucks market continue to trend upward. In May, inventory was up 1.83% M/M and 25.79% YOY. The used moving box truck category posted the largest M/M inventory increase at 19.51%, while used reefer box trucks had the largest per-category YOY inventory increase at 85.92%. Asking and auction values in this market have been trending downward for nine months. In May, asking values declined 0.97% M/M and 2.83% YOY, led by decreases in the used stake truck category, down 5.62% M/M, and the used moving truck category, down 7.86% YOY. Auction values decreased by 0.55% M/M and 1.73% YOY in May. Category leaders were used stake trucks, with auction values decreasing 5.89% M/M, and used reefer box trucks, with auction values down 6.84% YOY. U.S. Used Heavy-Duty Construction Equipment Inventory levels in this market have been trending downward for five months. In May, inventory levels increased by 1.23% M/M but were down 2.52% YOY. The used wheel loader category exhibited the largest M/M inventory increase at 1.7%, while used crawler excavators posted the largest YOY inventory decrease at 5.83%. Asking values are on a steady trend despite decreases of 1.9% M/M and 3.91% YOY in May. Used dozers led other categories in M/M asking value decreases at 2.46%, while used crawler excavators led other categories in YOY asking value decreases at 5.11%. Auction values are also trending sideways, with decreases of 0.69% M/M and 1.4% YOY in May. The used dozer category posted the largest M/M auction value decrease at 1.85%, while used wheel loaders had the largest per-category YOY auction value decrease at 5.42%. U.S. Used Medium-Duty Construction Equipment Inventory levels in the U.S. used medium-duty construction market are trending down, with a 0.48% increase M/M, and a 2.06% decrease YOY in May. Used wheeled skid steers showed the largest M/M inventory increase at 4.85%, while used mini excavators exhibited the largest YOY inventory decrease at 11.98%. Asking values in this market are trending sideways, with a 0.92% decrease M/M and a 3.05% decrease YOY. The used loader backhoes category showed the largest M/M asking value decrease at 1.8%, while used track skid steers exhibited the largest YOY asking value decrease at 4.69%. Auction values are trending up despite May decreases of 0.81% M/M and 0.82% YOY. The used loader backhoes category showed the largest M/M auction value decrease at 2.6% and the largest YOY auction value decrease at 3.29%. U.S. Used Lifts Inventory levels in the U.S. used lifts market have been trending upward, despite a slight decrease of 0.52% M/M in May, and are 14.3% higher YOY. The used pneumatic-tire forklift category exhibited the largest M/M inventory increase at 8.1%, while the used rough terrain scissor lift category showed the most significant YOY inventory growth at 31.89%. Asking values in this market decreased by 0.95% M/M and 8.16% YOY, maintaining a downward trend. The used rough terrain scissor lift category posted the largest M/M asking value decrease at 2.81%, and also showed the steepest YOY decline at 16.67%. Auction values decreased by 3.53% M/M and 7.04% YOY in May but kept a sideways trend. The used rough terrain scissor lift category experienced the largest M/M auction value decrease at 11.78%, and also had the largest YOY decrease at 13.82%. U.S. Used Tractors 100 Horsepower and Greater Inventory levels of U.S. used tractors 100 horsepower and greater declined 2.5% M/M and 0.66% YOY in May, following a downward trend. The used 100- to 174-HP tractor category had the largest impact on this market, with inventory falling 4.8% M/M and 9.59% YOY. Asking values decreased 1.88% M/M and 6.41% YOY and are trending downward. The used high-horsepower tractor category (tractors 300 HP and greater) showed both the largest M/M asking value decrease, down 2.94%, and the largest YOY decrease, down 6.63%. Despite auction values falling 2.09% M/M and 4.1% YOY in May, they are on a sideways trend. Sandhills observed the largest M/M decrease in the used high-HP tractor category, down 3.21%, and the most significant YOY decrease in the used 175- to 299-HP tractor category, down 3.84%. The EVI spread, which measures the percentage difference between asking and auction values, maintained at 38%, still slightly lower than peak values observed in 2015. U.S. Used Combines Inventory levels of used combine harvesters decreased by 0.11% M/M in May and were down 5.54% compared to year-ago levels. Despite the decline, this market is trending up. Asking values maintained an upward trend, rising 0.95% M/M and 0.15% YOY in May. Auction values continued a five-month upward trend in May, increasing 2.43% M/M and 7.71% YOY. The EVI spread continued to fall, reaching 42%, which is lower than peak values observed in 2015. U.S. Used Sprayers Inventory levels of U.S. used sprayers on Sandhill platforms have maintained a downward trend. In May, inventory decreased by 3.34% M/M and 5.22% YOY. Asking values for used sprayers are trending downward, with decreases of 2.09% M/M and 5.79% YOY in May. Auction values for used sprayers are following a steady trend but dipped 2.26% M/M and 3.7% YOY in May. The EVI spread 43%, only slightly lower than peak values from 2015. U.S. Used Planters Inventory levels of U.S. used planters on Sandhills platforms are trending downward. In May, inventory decreased by 3.7% M/M and 13.49% YOY. Asking values in this market have maintained a steady trend. However, asking values decreased by 3.54% M/M and 2.04% YOY in May. Auction values are also trending sideways, decreasing by 6.13% M/M but increasing by 6.70% YOY in May. The EVI spread increased to 55%, still lower than peak values observed in 2015. U.S. Used Compact and Utility Tractors Inventory levels of U.S. used compact and utility tractors on Sandhills platforms have been trending downward for seven months in a row. Inventory levels dropped 3.8% M/M and 24.06% YOY in May. The used less-than-40-HP tractor category exerted the greatest influence on inventory levels, with decreases of 5.62% M/M and 27.74% YOY. Asking values continued an upward trend, posting a slight 0.11% M/M increase and 1.18% YOY decrease. The used 40- to 99-HP tractor category showed the largest YOY decrease at 3.26%. Auction values showed a marginal 0.4% M/M decrease and a 0.3% YOY increase and are trending sideways. The used less-than-40-horsepower tractor category had the largest YOY decrease at 1.69%. Obtain the Full ReportsFor more information or to receive detailed analysis from Sandhills Global, contact us at marketreports@ About Sandhills GlobalSandhills Global is an information processing company headquartered in Lincoln, Nebraska. Our products and services gather, process, and distribute information through trade publications, websites, and online services that connect buyers and sellers across the construction, agriculture, forestry, oil and gas, heavy equipment, commercial trucking, and aviation industries. Our integrated, industry-specific approach to hosted technologies and services offers solutions that help businesses large and small operate efficiently and grow securely, cost-effectively, and successfully. Sandhills Global—we are the cloud. About the Sandhills Equipment Value IndexThe Sandhills Equipment Value Index (EVI) is a principal gauge of the estimated market values of used assets—both currently and over time—across the construction, agricultural, and commercial trucking industries represented by Sandhills Global marketplaces, including and other industry-specific equipment platforms. Powered by Value Insight Portal (VIP), Sandhills' proprietary asset valuation tool, Sandhills EVI provides useful insights into the ever-changing supply-and-demand conditions for each industry. Contact
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Follicular Lymphoma Market Growth Accelerates at a CAGR of 6% During the Forecast Period (2025-2034) Due to the Advancements in Targeted Therapies
The follicular lymphoma market is expanding due to several factors. Increased awareness of the disease has led to a higher number of treated cases, contributing to market growth. Additionally, the rising number of clinical trials focused on the different treatment options for follicular lymphoma is a significant driver of its market's expansion. LAS VEGAS, June 4, 2025 /PRNewswire/ — Follicular lymphoma is a typically slow-progressing B-cell lymphoproliferative disease that originates from transformed follicular center B cells. It is commonly marked by widespread lymph node enlargement, involvement of the bone marrow, and an enlarged spleen, while extranodal manifestations are relatively rare. As of 2024, approximately 35,000 cases of follicular lymphoma have been diagnosed across the 7MM, with both males and females having equal chances of getting the disease. First-line treatment for follicular lymphoma is well-established, with most patients experiencing durable responses to chemoimmunotherapy (CIT). For patients with localized disease, radiotherapy (RT) alone or in combination with immunochemotherapy is commonly used. RT alone may also be an option for localized relapses. Learn more about follicular lymphoma treatment guidelines @ Follicular Lymphoma Treatment Market The follicular lymphoma treatment landscape is broad and continuously evolving, offering multiple options for both newly diagnosed and relapsed/refractory (R/R) cases. Rituximab is the primary treatment option across the lines. It takes the highest market share as well as patient share. The availability of rituximab biosimilars has enhanced accessibility and affordability, maintaining its importance in managing the disease. Apart from rituximab, GAZYVA/GAZYVARO (obinutuzumab), which, when combined with chemotherapy, has become a key component in first-line treatment strategies. Its effectiveness in both treatment-naïve and relapsed patients has reinforced its central role in clinical practice. LUNSUMIO (mosunetuzumab) is a bispecific antibody therapy designed to treat adults with R/R follicular lymphoma who have already received two or more prior treatments. Approved in 2023, LUNSUMIO has already captured ~10% patient share in the third line of therapy. Furthermore, the future approvals in earlier lines can boost its market share. Multiple targeted therapies are making significant contributions. TAZVERIK (tazemetostat), an EZH2 inhibitor, provides a precision medicine approach for patients with specific genetic mutations. BRUKINSA (ibrutinib), a Bruton's tyrosine kinase inhibitor, although primarily approved for other B-cell cancers, also plays a role in follicular lymphoma treatment. Recent approvals have further expanded the arsenal, including EPKINLY/TEPKINLY (epcoritamab), a bispecific antibody targeting CD3 and CD20, as well as CAR T-cell therapies such as KYMRIAH (tisagenlecleucel), YESCARTA (axicabtagene ciloleucel), and BREYANZI (lisocabtagene maraleucel). These innovative immunotherapies are showing encouraging outcomes, particularly in the R/R setting, and are poised to reshape the therapeutic approach to follicular lymphoma by offering deeper and potentially long-lasting remissions. Find out more on FDA-approved follicular lymphoma treatment @ Follicular Lymphoma Drugs Market While ongoing research continues to explore new treatments, many approved therapies are already making a significant impact in the follicular lymphoma treatment landscape. The forecast period (2024–2034) is expected to bring further advancements, with emerging therapies enhancing existing treatment options. As healthcare spending continues to increase worldwide, the Follicular lymphoma treatment space is anticipated to see a positive shift, with more accessible and effective therapies becoming available to patients in need. Numerous drugs are currently in development for the treatment of follicular lymphoma, including promising therapies like Zilovertamab Vedotin (Merck Sharp and Dohme), CALQUENCE (acalabrutinib) (AstraZeneca), CTX112 (CRISPR Therapeutics), BGB-16673 (BeiGene), NKTR-255 (Nektar Therapeutics), NVG-111 (NovalGen), AS-1763 (docirbrutinib) (Carna Biosciences), Cemacabtagene Ansegedleucel (ALLO-501) (Allogene Therapeutics), Abexinostat (Xynomic Pharmaceuticals), Golcadomide (Bristol-Myers Squibb), MONJUVI (tafasitamab) (Incyte Corporation), AZD0486 (AstraZeneca), and others, which are set to launch in the 7MM during the forecast period (2024–2034). Discover which therapies are expected to grab major follicular lymphoma market share @ Follicular Lymphoma Therapy MONJUVI (tafasitamab) is a humanized monoclonal antibody that targets CD19 and has been engineered with an Fc domain to enhance cytolytic activity. It binds to CD19 proteins on B-cell surfaces, inhibiting their function and triggering cell death. The antibody works through apoptosis and immune-mediated mechanisms, including Antibody-dependent Cell-mediated Cytotoxicity (ADCC) and Antibody-dependent Cellular Phagocytosis (ADCP). In 2010, MorphoSys secured global exclusive rights to develop and commercialize tafasitamab from Xencor, Inc., which developed the Fc-engineered XmAb technology incorporated in the drug. In December 2024, Incyte presented pivotal findings from the Phase III inMIND trial at the ASH Annual Meeting. The study showed that combining MONJUVI with lenalidomide and rituximab significantly extended progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma, achieving both the primary PFS endpoint and key secondary measures. AZD0486 (previously TNB-486) is an innovative CD19xCD3 bispecific T-cell engager (TCE) built on an IgG4 backbone. It features a low-affinity anti-CD3 domain designed to limit cytokine release while maintaining robust T-cell-driven cytotoxicity against malignant B cells. The molecule has a silenced Fc region to avoid nonspecific binding and ADCC, while ensuring prolonged half-life for intermittent dosing. AZD0486 is currently in Phase III development for follicular lymphoma. In November 2024, at ASH 2024, AstraZeneca emphasized its growing hematology pipeline through two oral presentations on AZD0486. Phase I trial data revealed strong efficacy in R/R follicular lymphoma patients, with an overall response rate (ORR) of 96% and a complete response rate (CRR) of 85% at doses of 2.4 mg and higher. Discover more about drugs for follicular lymphoma in development @ Follicular Lymphoma Clinical Trials The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the US market size for follicular lymphoma is expected to grow from USD 1 billion in 2024 at a significant CAGR by 2034. The follicular lymphoma market is experiencing steady growth, driven by rising incidence rates, increasing awareness, and advancements in targeted therapies such as monoclonal antibodies and CAR-T cell treatments. The aging global population further contributes to market expansion. Additionally, ongoing clinical trials and approvals of novel agents are expected to boost market opportunities in the coming years. DelveInsight's latest published market report, titled as Follicular Lymphoma Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the follicular lymphoma country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The follicular lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Incidence Cases of Follicular Lymphoma Gender-specific Cases of Follicular Lymphoma Age-specific cases of Follicular Lymphoma Stage-Specific Cases of Follicular Lymphoma Grade-Specific Cases of Follicular Lymphoma Treated Case by Line of Therapy of Follicular Lymphoma The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM follicular lymphoma market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this follicular lymphoma market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the follicular lymphoma market. Also, stay abreast of the mitigating factors to improve your market position in the follicular lymphoma therapeutic space. Related Reports Follicular Lymphoma Epidemiology Forecast Follicular Lymphoma Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted follicular lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Follicular Lymphoma Pipeline Follicular Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key follicular lymphoma companies, including Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, among others. Non-Hodgkin's Lymphoma Market Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Non-Hodgkin's Lymphoma Pipeline Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Malaysian Reserve
6 hours ago
- Malaysian Reserve
MemorialCare Heart & Vascular Institute Completes First Successful TriClip Procedure for Tricuspid Valve Repair
LONG BEACH, Calif., June 4, 2025 /PRNewswire/ — The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology David Shavelle, M.D., performed Long Beach Medical Center's first transcatheter tricuspid valve replacement procedure using a new, innovative treatment option – the transcatheter edge-to edge repair (TEER) TriClip G4 System in September of 2024. The FDA-approved TriClip is a small clipping device designed to clip two or more of the leaflets of the tricuspid, offering a minimally invasive treatment option to patients who have tricuspid regurgitation (TR) – a condition where the tricuspid valve does not close completely when the right ventricle contracts. This device – implanted via a catheter inserted in the vein of the leg – helps reduce tricuspid regurgitation and promotes an immediate improvement in blood flow and allows patients to benefit from a less traumatic procedure and a faster recovery. This advanced technology marks a new era for treating tricuspid valve disease since prior to its introduction, patients could only receive a device better suited for the mitral valve (MitraClip® device). The TriClip device was specifically made for the tricuspid valve. In a large clinical trial, the device was shown to reduce symptoms and hospitalization for heart failure for patients at high-risk for open-heart surgery. 'This new procedure represents a significant advancement in our ability to treat high-risk patients with tricuspid valve heart disease,' says Dr. Shavelle, who led the landmark procedure. 'Historically there wasn't much we could do for those who still had symptoms after tricuspid regurgitation treatment and who were at high-risk for open heart surgery. This device gives patients access to improved quality of life.' This procedure was performed by a highly skilled, diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists and advanced imaging specialists from the MemorialCare Heart & Vascular Institute at Long Beach Medical Center. Implantation of the TriClip with the TriClip G4 System is as effective as open-heart surgery, helping patients return to their daily lives in one to two days. 'The patient recovered in the hospital for about two days, and he was able to return to his daily life the following day,' says Dr. Shavelle. 'It's amazing to see the positive impact this device has on our patients, allowing them to return to their daily lives with improved heart function and overall well-being.' The patient who received this procedure, Anthony Williams, reported being fatigued constantly with excessive swelling of the legs (edema) before the procedure. Today, he is more energetic than ever and ready to take on each day. MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the first institute in the region to use this device and continues to lead in cardiovascular innovations, bringing patients with the latest technology advancements. As one of the most high performing hospitals according to U.S. News, MemorialCare Long Beach Medical Center is a six-time five-star recipient recognized for its excellence in cardiac care by Healthgrades, and has recently received the American Heart Association's Get With The Guidelines® Heart Failure Gold Plus Quality Achievement Award, as well as the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plus Quality Achievement Award. With these achievements and offering a comprehensive range of services for patients with cardiac disorders, including rehabilitation programs, Long Beach Medical Center is a community hospital dedicated in providing expert and compassionate care on par with those found in academic settings. About MemorialCare Long Beach Medical Center: MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as 'Best Hospital' for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit
